Avacta sees Covid-19 tests driving earnings after reporting 2020 loss
Avacta sees Covid-19 tests driving earnings after reporting 2020 loss
Read moreAvacta sees Covid-19 tests driving earnings after reporting 2020 loss
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.
Read moreIN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial
Read moreAIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Avacta in global Affimer distribution agreement with Abcam
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.
Read moreEXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down
Read moreIN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit
Read more(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.
Read moreIN BRIEF: Avacta's Covid antigen test confirmed to detect variants
Read more(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.
Read moreTRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End
Read moreAIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone
Read moreAIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans
Read more